Statement of Need

Hypoglycemia is a common complication of treatment that negatively impacts quality of life and elicits fears in patients with diabetes. Severe episodes, in which the person requires assistance from others, can have negative health consequences such as increased mortality. Identifying patients who are at risk for severe episodes and making sure they and their caregivers are prepared can improve outcomes. Yet, many patients are not prepared, and guideline-recommended glucagon is under prescribed in eligible patients.

Target Audience

This activity is intended for the multispecialty clinical team across physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare providers who manage patients with diabetes and play a role in helping patients prevent and/or prepare for a severe hypoglycemic event.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patient-level predictors of severe hypoglycemia and related morbidity
  • Discuss the barriers to recognizing and treating severe hypoglycemia
  • Utilize strategies to increase and optimize the prevention and preparedness for severe hypoglycemia
  • Implement patient education approaches to improve success rates for glucagon administration for severe hypoglycemic events

Method of Participation

This activity will take up to 2 hours complete. To receive credit, participants are required to complete the questionnaire, action plan, and view the online interventions during the assess stage. After a minimum of 30 days, participants are required to again complete the questionnaire and action plan, as well as an evaluation and reflection. A certificate will be available upon completion. There is no fee to participate in the activity or for the generation of the certificate.

CPE/ABIM credit will be submitted to CPE Monitor®/ABIM within 30 days of completion.

Accreditation and Credit Designation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Purdue University College of Pharmacy designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Continuing Pharmacy Education Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

This activity has been approved for 1.0 contact hour.

  • ACPE Universal Activity Number: 0018-9999-22-024-H01-P
  • Activity Type(s): Application
  • Release Date: September 22, 2022
  • Expiration Date: September 22, 2023


Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This program is approved for 2.0 contact hours.


This activity is approved for 2.0 contact hour(s) of continuing education (which includes 0.00 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22095778. This activity was planned in accordance with AANP Accreditation Standards and Policies.


This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 9/22/2022 to 9/22/2023. AAPA reference number: CME-207779.


To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

The following financial relationships have been provided:

Davida F. Kruger, MSN, APN-BC, BC-ADM

  • Consultant: Abbott, Cequr, Modular Medical, Novo Nordisk, Sanofi
  • Research Support: Abbott, Beta Bionics, Dexcom, Novo Nordisk,
  • Speaker: Cequr, Dexcom, Lilly, Novo Nordisk, Sanofi, Xeris
  • Stock: Pendulum

Anne Louise Peters, MD

  • Advisory Board: Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Novo Nordisk, Zealand
  • Research Support: Abbott Diabetes Care, Dexcom, Insulet
  • Stock/Stock Options: Omada Health, Teladoc

All relevant conflicts of interest have been mitigated prior to the start of the activity.

None of the planners, reviewers, ACHL, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None


This activity is sponsored by Purdue University College of Pharmacy, in partnership with the Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an educational grant from Lilly.